Royalty PharmaRPRX 
$25.000.64%24h
0.64%24h
Global rank673
Market cap$11.19B
Change 7d-4.03%
YTD Performance-10.68%
SP500 benchmarkUnderperform
P/E9.88
P/S4.75
Revenue$2.35B
Earnings$1.70B
Dividend yield3.2%
Main Sector
Healthcare
Royalty Pharma RPRX Total Debt
RPRX Total Debt in 2022: $6.14B
According to Royalty Pharma latest financial reports the total debt is $6.14B, an increase of 0.27% to 2022. At the end of 2022 company had $6.12B total debt. This figure represents the debts and financial obligations that Royalty Pharma combine short-term debt, long-term debt, and other fixed payment obligations (such as capital leases) of a business that are incurred while under normal operating cycles.
Royalty Pharma RPRX Total Debt History from 2023 to 2022
-
Value:-
RPRX Total Debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023 | $6.14B | 0.27% |
| 2022 | $6.12B | -13.77% |
| 2021 | $7.10B | 22.00% |
| 2020 | $5.82B | -2.34% |
| 2019 | $5.96B | -4.52% |
| 2018 | $6.24B | - |
View the Top Total Debt Stocks 
